Combined Tumor-Based BRCA1/2 and TP53 Mutation Testing in Ovarian Cancer

Somatic/germline BRCA1/2 mutations (m)/(likely) pathogenic variants (PV) (s/gBRCAm) remain the best predictive biomarker for PARP inhibitor efficacy. As >95% of high-grade serous ovarian cancers (HGSOC) have a somatic TP53m, combined tumor-based BRCA1/2 (tBRCA) and TP53 mutation testing (tBRCA/TP...

Descripción completa

Detalles Bibliográficos
Autores principales: Borcoman, Edith, Santana dos Santos, Elizabeth, Genestie, Catherine, Pautier, Patricia, Lacroix, Ludovic, Caputo, Sandrine M., Cabaret, Odile, Guillaud-Bataille, Marine, Michels, Judith, Auguste, Aurelie, Leary, Alexandra, Rouleau, Etienne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10380272/
https://www.ncbi.nlm.nih.gov/pubmed/37511329
http://dx.doi.org/10.3390/ijms241411570

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10380272/
https://www.ncbi.nlm.nih.gov/pubmed/37511329
http://dx.doi.org/10.3390/ijms241411570

Ejemplares similares